• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Molecular basis for increased cardiovascular disease in older women

Cardiology, women's health, 26 August 2020/in E-News /by 3wmedia

Researchers have discovered the molecular basis for the increased incidence of cardiovascular diseases in older women. The study found that older women had mitochondrial dysfunction, reduced antioxidant proteins, and increased inflammation.
Previous studies have shown sex differences in the age at which cardiovascular diseases occur. Ischemic heart disease, for example, develops on average seven to ten years later in women compared with men. It occurs three to four times more often in men than in women below the age of 60 years, but after the age of 75, most patients are women.
It is not clear why many women are protected from cardiovascular disease at a young age but are more susceptible after menopause. Estrogen levels may play a role but the mechanism is unknown. This study looked at molecular changes in the cells of the heart that happen with ageing, and how they differ between men and women.
Specifically, the researchers looked at healthy hearts to see if there are sex differences in mitochondrial function and inflammation during ageing. Heart tissue was obtained from seven women and seven men aged 17 to 40 years, and from eight women and nine men aged 50 to 68 years. The researchers measured levels of proteins involved in inflammation and in the function of the mitochondria.
The researchers found that the levels of Sirt1, a protein that is important for the function of the mitochondria, are higher in young women compared to young men. In the older hearts, Sirt1 levels had decreased in women but not in men. Expression of superoxide dismutase 2, an antioxidant protein in the mitochondria, was higher in young females than males but the difference was no longer present with age.
In addition, the expression of catalase, an enzyme that protects cells from oxidative damage, was higher in young females than males but again the difference was lost with age.
With age, female hearts shifted from an anti-inflammatory to a pro-inflammatory environment. Compared to young men, young women had higher levels of anti-inflammatory cytokines such as interleukin 10 – but this difference was lost with age. Levels of macrophages, which promote inflammation, increased with age in women but not in men.
Dr Maria Luisa Barcena De Arellano, scientific researcher, Institute of Gender Medicine, Charité University Medicine Berlin, Germany, said: “Our study provides a molecular explanation for the increased incidence of cardiovascular diseases in older women.”

European Society of Cardiology
https://tinyurl.com/y8zah7gn

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192023-09-06 08:22:50Molecular basis for increased cardiovascular disease in older women

Study casts doubt on ketamine nasal sprays for depression

, 26 August 2020/in E-News /by 3wmedia

Researchers from the Black Dog Institute and UNSW Sydney have questioned the efficacy and safety of intranasal ketamine for depression, with their pilot trial stopped early due to poor side effects in patients.
Nasal spray devices have been touted as a promising way to deliver ketamine to patients with treatment-resistant depression, with this application easier to use and less invasive than other clinical delivery methods such as injections.
Yet contrary to previous trials, this latest study reveals the unpredictable nature of intranasal ketamine tolerance from one person to the next.
“It’s clear that the intranasal method of ketamine delivery is not as simple as it first seemed,” said lead author UNSW Professor Colleen Loo, who is based at Black Dog Institute.
“Many factors are at play when it comes to nasal spray ketamine treatments. Absorption will vary between people and can fluctuate on any given day within an individual based on such things as mucous levels in the nose and the specific application technique used.”
The pilot trial aimed to test the feasibility of repeated doses of ketamine through an intranasal device amongst 10 participants with severe depression, ahead of a larger randomised controlled trial.
Participants were first given extensive training in proper self-administration techniques before receiving either a course of eight ketamine treatments or an active control over a period of four weeks, under supervision at the study centre.
Following initial reactions to the nasal spray, the dosage was adjusted amongst study patients to include longer time intervals between sprays.
However, the pilot study was eventually suspended after testing with five participants due to unexpected problems with tolerability. Side effects included high blood pressure, psychotic-like effects and motor incoordination that left some participants unable to continue to self-administer the spray.  
“Intranasal ketamine delivery is very potent as it bypasses metabolic pathways, and ketamine is rapidly absorbed into the bloodstream,” said Professor Loo.
“But as our findings show, this can lead to problems with high peak levels of ketamine in some people causing problematic side effects.
“Other recent studies have questioned whether changes to ketamine’s composition after being metabolised into derivative compounds may actually deliver useful therapeutic effects.
“It remains unclear whether ketamine nasal sprays can be safely relied upon as a treatment for patients with severe depression.”
University of New South Walesnewsroom.unsw.edu.au/news/health/study-casts-doubt-ketamine-nasal-sprays-depression

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:32Study casts doubt on ketamine nasal sprays for depression

New antifungal provides hope in fight against superbugs

, 26 August 2020/in E-News /by 3wmedia

Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
Case Western Reserve University Medical Schoolcasemed.case.edu/cwrumed360/news-releases/release.cfm?news_id=906&news_category=8

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:39New antifungal provides hope in fight against superbugs

A new portable gel that could save an injured eye

, 26 August 2020/in E-News /by 3wmedia

When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics are in a high-stakes race against the clock.
A multidisciplinary team of scientists and engineers at USC are close to solving the problem. They have developed a reversible, temperature-sensitive temporary seal that changes from a fluid to a super-strong semi-solid when applied to the eye. When the patient is ready for surgery to permanently close the injury, doctors can remove the seal by adding cool water.
“If you look at historical data over the last several decades, the rate of war-related ocular injuries has steadily increased from a fraction of a percent to as high as 10 to 15 percent. Some of that can be attributed to changes in warfare, especially with the use of improvised explosive devices,” said corresponding author John Whalen, assistant professor of research ophthalmology at the USC Roski Eye Institute and member of the USC Institute for Biomedical Therapeutics. “When the Department of Defense asked the scientific community to develop novel approaches to treating ocular injuries, we immediately thought of an advanced material we had previously worked with as a possible adhesive for a retinal implant.”
The material the group was working with for retinal implants was a hydrogel called PNIPAM, poly(N-isopropylacrylamide), which had a unique attribute that made it a natural fit for this application: when cooled, the hydrogel became a liquid for easy application, and when heated, it became a viscous semi-solid with strong adhesion. All that was needed was some tailoring.
“Since the initial hydrogel’s transition temperature was very close to the temperature of the human eye, we had to modify its properties to ensure that it would form a solid seal as soon as the gel was applied to the eye by a soldier or medic,” said lead author Niki Bayat, a doctoral candidate in the Mork Family Department of Chemical Engineering and Materials Science at USC Viterbi. “Providing a perfect, yet reversible seal, the smart hydrogel shows promise for the next generation of tissue adhesives.”
When an ophthalmologist is ready to repair the eye, the hydrogel can be extracted by applying cool water and converting it back to a less adhesive state.
The research team also developed a special syringe for the hydrogel that would be easy to use on the front lines and capable of quickly cooling the hydrogel before application. The syringe has a cooling chamber filled with calcium ammonium nitrate crystals — the type used in instant ice cold packs. By adding water to the chamber, the crystals activate and cool the hydrogel to operating temperatures within 30 seconds.
“We were able to optimize the delivery device so that it not only rapidly cools the hydrogel but also holds it at that temperature, giving users a 10-minute window to fill penetrations in the eye,” Whalen said. “It’s very simple to use — almost like caulking a bathroom seal.”
The customized seal and delivery device will also reduce the amount of time it takes to close penetrating eye injuries overall.
“This temporary intervention could decrease repair time from 30 minutes or longer to less than five minutes, freeing up valuable time for first responders and trauma units,” said principal investigator Mark Humayun, University Professor of Ophthalmology and co-director of the USC Roski Eye Institute, director of the USC Institute for Biomedical Therapeutics and a professor of biomedical engineering at USC Viterbi.
University of Southern Californiahttps://tinyurl.com/y8eurz42

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:38A new portable gel that could save an injured eye

Probiotics useful in the fight against infection prevention

, 26 August 2020/in E-News /by 3wmedia

Probiotics may be a relatively safe, simple, and low-cost solution for preventing Clostridium difficile infections (CDI) in hospital settings, according to two studies. Both studies show that treating patients who received antibiotics with multi-strain probiotics, cut down on CDI incidence rates over time.
"While it’s not a perfect solution for a bacterium that has proven very difficult to prevent and treat, probiotics could offer patients another line of defence," said Bradley Johnston, PhD, associate professor of epidemiology at Dalhousie University in Canada and lead author of one of the studies. "We worked with clinical trialists from 12 countries that willingly shared their data with us to conduct what is known as an individual patient data meta-analysis and we demonstrated that we should be considering probiotics as a viable strategy for preventing CDI in patients."
The research led out of Dalhousie University in Canada conducted a synthesis of randomized controlled trials to determine whether probiotics reduced the odds of CDI in adults and children. It found that probiotics reduced the odds of CDI by about two-thirds in both their non-adjusted and adjusted models (adjusting for age, sex, hospitalization status, use of multiple antibiotics, and exposure to high-risk antibiotics). Additionally, they found that compared to no probiotics, multi-species probiotics were more beneficial than single-species probiotics.
This study analyzed 18 eligible randomized controlled trials that included patient data for 6,851 participants comparing probiotics to placebo or no treatment and that reported CDI as an outcome. Probiotics were especially effective among participants taking two or more antibiotics and in settings where the risk of CDI was greater than five percent.
A second project conducted by Cook County Health & Hospitals System at a separate tertiary care medical center, in which a single-center before-after quality improvement intervention was evaluated, found that probiotics provided a delayed benefit in reducing CDI. During the intervention period, there was a trend toward a lower incidence in CDI in the second six months, compared to the first six months. The authors speculate that the postponed benefit could be attributed to the time required for environmental contamination with spores of C. difficile to be brought under control.
"There is an expanding number of options to prevent or treat the often serious and costly infections caused by C. difficile," said William Trick, MD, a clinician at Cook County Health & Hospitals System and lead author of the study. "Probiotics are one option that is low cost, relatively safe, and likely beneficial in the long-run."
Trick and his team compared 12-month baseline and intervention periods. Patients in the study received capsules containing a three-strain probiotic mixture, to be taken within 12 hours of their antibiotics. The primary outcome of the study was the incidence of hospital-onset CDI among participants.
While this study showed the benefits of implementing probiotics as a strategy against CDI, it also highlighted the limitations in this approach. For instance, during a real-world quality improvement intervention, getting a probiotic agent to the right patients at the right time was challenging and led to incomplete use of the intervention. Also, the beneficial results are unlikely to match those reported in randomized controlled trials (RCTs). It is critical that interventions are tested in routine practice settings to uncover implementation challenges and to evaluate the replicability of results from RCTs in different settings.

The Society for Healthcare Epidemiology of America (SHEA)www.shea-online.org/index.php/journal-news/press-room/press-release-archives/588-probiotics-useful-in-the-fight-against-infection-prevention

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:27Probiotics useful in the fight against infection prevention

Canon Medical Systems Corporation acquires Fysicon B.V.

, 26 August 2020/in E-News /by 3wmedia

Fysicon announced on March 7 that it has been acquired by Canon Medical Systems Corporation.

Linda Elberse, CEO of Fysicon: "Being part of a major player as Canon Medical Systems Corporation gives us the opportunity to cover all parts of the world with our innovative systems. Now Canon Medical has completed the image by adding Fysicon’s new developed hemodynamic monitoring system “QMAPP”, the sophisticated device management system “DataLinQ” and the cloud based image distribution software “EVOCS" and last but not least Fysicon’s knowledge of connectivity and workflow management. Canon Medical is a strong brand name and a leading supplier, that will help us take the next steps into strengthening and growing our footprint in the global market. Furthermore we will keep developing new technologies and exploring new areas in the medical field together with our new parent company. We are very proud to have joined forces!”

Toshio Takiguchi, President of Canon Medical Systems, said: “We are really pleased that we can provide new clinical value to patients and medical professionals by combining Fysicon’s advanced technologies with our systems.“ 

About Fysicon
Fysicon was founded in 1996 and employs approximately 40 employees. The company is headquartered in the Netherlands (Oss) and has a subsidiary in the UK. Hospitals around the world are using Fysicon’s hardware and software to streamline cardiac workflows and manage their data exchange.
Fysicon designs, develops and produces innovative medical technologies in the areas of structural heart disease and medical imaging for hospitals, research institutes and industry. Both hardware as well as software are developed and produced in-house, to guarantee the highest level of quality.  Fysicon challenges healthcare by developing innovative, intuitive and high quality medical solutions for healthcare professionals empowering them to treat patients faster, better and more cost effective.www.fysicon.com 

About Canon Medical Sytems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including Ultrasound, CT, X-Ray, and MR, across the globe. On January 4, 2018, Toshiba Medical changed its company name to Canon Medical Systems Corporation. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide so that together our industry-leading solutions deliver an enriched quality of life.https://global.medical.canon

 

 

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:34Canon Medical Systems Corporation acquires Fysicon B.V.

Breakthrough technology to further understand eye damage from eclipse

, 26 August 2020/in E-News /by 3wmedia

In a first-of-its-kind study, Mount Sinai researchers are using adaptive optics (AO) to analyse retinal eye damage from the August solar eclipse on a cellular level. The research could help doctors develop a deeper understanding of this rare condition, called solar retinopathy, which has no currently accepted treatment.
Adaptive optics is a sophisticated technology that allows clinicians to examine microscopic structures of the eye in living patients with extreme detail in real time. Before the development of AO, researchers could only see this level of detail on glass slides with a microscope.
“We have never seen the cellular damage from an eclipse because this event rarely happens and we haven’t had this type of advanced technology to examine solar retinopathy until recently,” said lead investigator Avnish Deobhakta, MD, Assistant Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai. “NYEE is one of the few sites in North America with access to this technology, and using this to get an exact look at the patient’s retinal damage on such a precise level will help clinicians better understand the condition.”
Mount Sinai investigators used AO imaging on a patient who looked at the sun during the eclipse for 21 seconds without protective eyewear. Four hours later, the patient developed blurry distortion in both eyes and could only see the colour black. NYEE specialists examined her three days later and found she had burned a hole in her retinas and diagnosed her with solar retinopathy and photochemical burns.
Using this technology, researchers obtained high-resolution images of the damaged photoreceptors, which may provide a deeper understanding of the condition that could one day lead to the development of treatments.
“It’s exciting to be able to see such a correlation between the patient’s symptoms and the photoreceptor injury on a cellular level.  Hopefully this research allows us to potentially develop future therapies for solar retinopathy and other forms of photic injury to the retina,” said Chris Wu, MD, a resident physician at New York Eye and Ear Infirmary of Mount Sinai. “This study can prepare doctors and patients for the next eclipse in 2024, and make them more informed of the risks of directly viewing the sun without protective eyewear.”
Mount Sinai Health Systemhttps://tinyurl.com/y8cge588

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:42Breakthrough technology to further understand eye damage from eclipse

New blood pressure guidelines could put lives at risk

, 26 August 2020/in E-News /by 3wmedia

A new report by University of Sydney and Bond University scholars weighs the risks and benefits of a recent change to blood pressure guidelines in the US.
Recommendations from the American College of Cardiology and American Heart Association to lower thresholds defining hypertension and the treatment of higher risk patients are sparking debate, the report reveals.
The recommendations from American College of Cardiology and the American Heart Association are as follows:

  • lowering the threshold for diagnosing hypertension in adults from 140/80 mmHg to 130/80 mmHg
  • lowering the threshold for drug treatment of ‘high risk’ adults with hypertension who have existing CVD from 140/80 mmHg to 130/80 mmHg
  • lowering the threshold for drug treatment of adults with a calculated 10-year CVD risk ≥10 percent, or otherwise high risk, for example, people with diabetes or renal disease, from 140/80 mmHg to 130/80 mmHg.

Changing the diagnostic and treatment thresholds for hypertension could put people at risk in three ways, say the University of Sydney and Bond University authors of the report.
“First, wider disease definitions mean more people are labelled as unwell, even if they have low risk of a disease,” said the report’s lead author, Dr Katy Bell of the University of Sydney. “Labelling a person as having hypertension increases their risk of anxiety and depression, as compared to the risk for people with the same blood pressure who aren’t labelled as hypertensive.
“Second, it means more people may experience serious adverse effects from treatments.
“Third, in countries without universal health coverage, such as the United States, people newly diagnosed with hypertension may face difficulties gaining insurance coverage for a ‘pre-existing’ condition.”
Report co-author, Bond University Professor Paul Glasziou said: “The ACC/AHA guideline follow an established pattern in the medical specialties, where disease definitions are more often widened than narrowed.
“Systolic blood pressure has poor reproducibility, with a 10mmHg standard deviation for repeat measurements between clinics,” he added.
“Since a large proportion of all adults have a ‘true’ systolic blood pressure near the threshold of 130 mm Hg, the inherent variability of blood pressure increases the potential that hypertension will be diagnosed.”
The report says 80 percent of people with newly diagnosed hypertension under the ACC/AHA guideline would get no expected benefit in terms of cardiovascular disease risk reduction by lowering their blood pressure. Eleven per cent would get a marginal benefit and nine per cent would get a larger benefit.
However, the 2017 ACC/AHA guideline would classify an additional 13.7 percent of all adults as having hypertension – 31 million additional people in the United States as having hypertension, and around 2.4 million additional Australians.
For the majority of these people, who are at low risk and not recommended for drug treatment (about 25 million), the authors say doctors should not label them as having hypertension.
“Doctors should continue to support healthy choices with regard to diet and physical activity regardless of whether a patient’s systolic blood pressure is above or below 130 mmHg,” said Bond University co-author, Professor Jenny Doust. “When there is a question of starting blood pressure medication, the risk of cardiovascular disease should be estimated using a reliable risk calculator and the potential benefits and harms discussed with the patient”.

University of Sydneyhttps://tinyurl.com/yb6benfj

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:22New blood pressure guidelines could put lives at risk

Smartphone ‘scores’ can help doctors track severity of Parkinson’s disease

, 26 August 2020/in E-News /by 3wmedia

Parkinson’s disease, a progressive brain disorder, is often tough to treat effectively because symptoms, such as tremors and walking difficulties, can vary dramatically over a period of days, or even hours.
To address this challenge, Johns Hopkins University computer scientists, working with an interdisciplinary team of experts from two other institutions, have developed a new approach that uses sensors on a smartphone to generate a score that reliably reflects symptom severity in patients with Parkinson’s disease.
In a study researchers from Johns Hopkins’ Whiting School of Engineering, the University of Rochester Medical Center, and Aston University in the U.K. reported that the severity of symptoms among Parkinson’s patients seen by neurologists aligned closely with those generated by their smartphone app.
Typically, patients with Parkinson’s disease are evaluated by medical specialists during three or four clinic visits annually with subjective assessments capturing only a brief snapshot of a patient’s fluctuating symptoms. In their homes, patients may also be asked to fill out a cumbersome 24-hour “motor diary” in which they keep a written record of their mobility, involuntary twisting movements and other Parkinson’s symptoms. The doctor then uses this self-reported or imprecise data to guide treatment.
In the new study, the researchers say patients could use a smartphone app to objectively monitor symptoms in their home and share this data to help doctors fine-tune their treatment.
E. Ray Dorsey, a University of Rochester Medical Center neurologist and a co-author of the research paper, said he welcomes the validation of Parkinson’s patient severity scores produced by the smartphone tests.
About six years ago, while doing medical research at Johns Hopkins, Dorsey was introduced to Suchi Saria, an assistant professor of computer science at the universityThe two researchers, along with some of Saria’s students, teamed up to find a way to monitor the health of Parkinson’s patients as easily as people with diabetes can check their glucose levels with a pinprick blood test.
The team members knew that neurologists evaluated their Parkinson’s patients by gathering information about how they moved, spoke and completed certain daily tasks. “Can we do this with a cellphone?” Saria wondered at the time. “We asked, ‘What are the tricks we can use to make that happen?’ ”
Using existing smartphone components such as its microphone, touch screen and accelerometer, the team members devised five simple tasks involving voice sensing, finger tapping, gait measurement, balance and reaction time. They turned this into a smartphone app called ‘HopkinsPD.’ Next, using a machine learning technique that the team devised, they were able to convert the data collected with these tests and turn that into an objective Parkinson’s disease severity score—a score that better reflected the overall severity of patients’ symptoms and how well they were responding to medication.
Johns Hopkins Universityreleases.jhu.edu/2018/04/05/smartphone-scores-can-help-doctors-track-severity-of-parkinsons-disease-symptoms/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:29Smartphone ‘scores’ can help doctors track severity of Parkinson’s disease

Faster, more accurate cancer detection using nanoparticles

, 26 August 2020/in E-News /by 3wmedia

Using light-emitting nanoparticles, Rutgers University-New Brunswick scientists have invented a highly effective method to detect tiny tumours and track their spread, potentially leading to earlier cancer detection and more precise treatment.
The technology could improve patient cure rates and survival times.
“We’ve always had this dream that we can track the progression of cancer in real time, and that’s what we’ve done here,” said Prabhas V. Moghe, a corresponding author of the study and distinguished professor of biomedical engineering and chemical and biochemical engineering at Rutgers-New Brunswick. “We’ve tracked the disease in its very incipient stages.”
The study shows that the new method is better than magnetic resonance imaging (MRI) and other cancer surveillance technologies. The research team included Rutgers’ flagship research institution (Rutgers University-New Brunswick) and its academic health centre (Rutgers Biomedical and Health Sciences, or RBHS).
“The Achilles’ heel of surgical management for cancer is the presence of micro metastases. This is also a problem for proper staging or treatment planning. The nanoprobes described in this paper will go a long way to solving these problems,” said Steven K. Libutti, director of Rutgers Cancer Institute of New Jersey. He is senior vice president of oncology services for RWJBarnabas Health and vice chancellor for cancer programmes for Rutgers Biomedical and Health Sciences.
The ability to spot early tumours that are starting to spread remains a major challenge in cancer diagnosis and treatment, as most imaging methods fail to detect small cancerous lesions. But the Rutgers study shows that tiny tumours in mice can be detected with the injection of nanoprobes, which are microscopic optical devices, that emit short-wave infrared light as they travel through the bloodstream – even tracking tiny tumours in multiple organs.
The nanoprobes were significantly faster than MRIs at detecting the minute spread of tiny lesions and tumours in the adrenal glands and bones in mice. That would likely translate to detection months earlier in people, potentially resulting in saved lives, said Vidya Ganapathy, a corresponding author and assistant research professor in the Department of Biomedical Engineering.
“Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go,” she said. “You can treat the tumours intelligently because now you know the address of the cancer.”
The technology could be used to detect and track the 100-plus types of cancer, and could be available within five years, Moghe said. Real-time surveillance of lesions in multiple organs should lead to more accurate pre- and post-therapy monitoring of cancer.
“You can potentially determine the stage of the cancer and then figure out what’s the right approach for a particular patient,” he said.
In the future, nanoprobes could be used in any surgeries to mark tissues that surgeons want to remove, the researchers said. The probes could also be used to track the effectiveness of immunotherapy, which includes stimulating the immune system to fight cancer cells.
Rutgers Universityhttps://tinyurl.com/yblku22y

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:37Faster, more accurate cancer detection using nanoparticles
Page 211 of 231«‹209210211212213›»

Latest issue of International Hospital

April 2024

3 July 2025

EEG-powered brain computer interface enables finger-level robotic hand control

2 July 2025

Scientists identify ‘traumome’ targets for rapid emergency trauma treatment

1 July 2025

BMJ investigation reveals AstraZeneca’s billion-dollar heart drug built on flawed data

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription